IBio Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:3em;'>IBI</div>
IBIO -- USA Stock  

USD 1.49  0.03  1.97%

Today we may see the proof that Precision BioSciences would recover much slower from the new pull down as its shares went up 8.69% to IBio's 8.9888%. While many traders are getting carried away by overanalyzing competition within healthcare space, it is quite reasonable to outline both, IBio and Precision BioSciences as potential short-term investments. We are going to inspect some of the competitive aspects of both IBio and Precision.
Published over two weeks ago
View all stories for IBio | View All Stories
Are retail investors picking up IBio (NYSEMKT:IBIO) or Precision BioSciences?
By analyzing existing basic indicators between IBio and Precision, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Precision with a short position in IBio. Check out our pair correlation module for more information.

Let's begin by analyzing the assets. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. IBio has an asset utilization ratio of 3.18 percent. This suggests that the company is making $0.0318 for each dollar of assets. An increasing asset utilization means that IBio Inc is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as IBio or DYADIC is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is IBio's Liquidity

IBio financial leverage refers to using borrowed capital as a funding source to finance IBio Inc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. IBio financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between IBio's total debt and its cash.

Correlation Between IBio and DYADIC INTERNATIONAL INC

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding IBio together with similar or unrelated positions with a negative correlation. For example, you can also add DYADIC INTERNATIONAL to your portfolio. If DYADIC INTERNATIONAL is not perfectly correlated to IBio it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When IBio for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down. Please check pair correlation details between IBIO and DYAI for more information.

Acquisition by Maddux Randy Joe of 465000 shares of IBio subject to Rule 16b-3

Legal trades by IBio insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
IBio insider trading alert for grant of stock option by Maddux Randy Joe, Chief Operating Officer, on 2nd of December 2020. This event was filed by Ibio Inc with SEC on 2020-12-02. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down IBio Indicators

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Let me now analyze IBio revenue. Based on the latest financial disclosure, IBio Inc reported 1.64 M of revenue. This is 99.98% lower than that of the Healthcare sector and 99.78% lower than that of the Biotechnology industry. The revenue for all United States stocks is 99.98% higher than that of IBio. As for Precision BioSciences we see revenue of 21.96 M, which is 97.04% lower than that of the Biotechnology

742.9 M
IBIO1.64 Million0.21
Sector742.91 Million96.92
DTIL21.96 Million2.86

Will IBio latest rise continue?

Value At Risk just dropped to -8.7, may entail upcoming price decrease. IBio Inc is displaying above-average volatility over the selected time horizon. Investors should scrutinize IBio Inc independently to ensure intended market timing strategies are aligned with expectations about IBio volatility.

Our Takeaway on IBio Investment

Whereas many other companies in the biotechnology industry are either recovering or due for a correction, IBio may not be performing as strong as the other in terms of long-term growth potentials. To sum up, as of the 16th of November 2020, our research shows that IBio is a rather dangerous investment opportunity with a low odds of financial turmoil in the next two years. From a slightly different view, the entity currently appears to be undervalued. However, our concluding 30 days buy vs. sell advice on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of IBio Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com